Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The qMSP analyses revealed that LZTS2 promoter methylation levels in the LSCC tumor samples were significantly higher than those in paired adjacent healthy tissue samples.
|
29499699 |
2018 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The leucine zipper tumor suppressor 2 (LZTS2) was identified as a tumor susceptibility gene within the 10q24.3 chromosomal region, and is approximately 15Mb from the PTEN locus.
|
28323888 |
2017 |
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
These data provide the first line of evidence demonstrating that deletion of Lzts2 increases susceptibility to spontaneous and carcinogen-induced tumor development.
|
23275340 |
2013 |
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The LZTS2 gene is located at 10q24.3, which is frequently lost in a variety of human tumors.
|
17000760 |
2006 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
LAPSER1: a novel candidate tumor suppressor gene from 10q24.3.
|
11709705 |
2001 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In conclusion, our results demonstrate the critical role of miR-300 in GSLCs and its functions in LZTS2 inhibition and describe a new approach for the molecular regulation of tumor stem cells.
|
24464870 |
2014 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We found that low levels of LZTS2 in NSCLC were correlated with tumor and nodal status.
|
23761130 |
2013 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
LZTS2 (leucine zipper tumor suppressor 2), a candidate tumor suppressor gene, suppresses cell growth and plays a vital role in the carcinogenesis and development of tumors.
|
29499699 |
2018 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate the significance of simultaneous Pten and Lzts2 deletion in oncogenic transformation in prostate cells and implicates a new mechanism for the dysregulation of Wnt/β-catenin signaling in prostate tumorigenesis.
|
28323888 |
2017 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Functionally, we showed that LZTS2 suppresses tumorigenesis and radioresistance in nasopharyngeal carcinoma in a p85-dependent manner.
|
29409973 |
2018 |
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using an Lzts2 knock-out mouse model, we characterized the biological role of Lzts2 in tumorigenesis.
|
23275340 |
2013 |
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription.
|
28323888 |
2017 |
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells.
|
23275340 |
2013 |
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription.
|
28323888 |
2017 |
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells.
|
23275340 |
2013 |
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
|
17351128 |
2007 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.
|
11709705 |
2001 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
|
17351128 |
2007 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.
|
11709705 |
2001 |
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
|
17351128 |
2007 |
Carcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We observed that mice with both Lzts2 and Pten deletion have an earlier onset of prostate carcinomas as well as an accelerated tumor progression compared to mice with Pten or Lzts2 deletion alone.
|
28323888 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that low levels of LZTS2 in NSCLC were correlated with tumor and nodal status.
|
23761130 |
2013 |